Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well docetaxel and capecitabine work in
treating patients with squamous cell (thin, flat cells) carcinoma of the head and neck that
has come back or spread to other places in the body. Drugs used in chemotherapy, such as
docetaxel and capecitabine, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.